Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis

Dipak Kotecha, Jane Holmes, Henry Krum, Douglas G Altman, Luis Manzano, John G F Cleland, Gregory Y H Lip, Andrew J S Coats, Bert Andersson, Paulus Kirchhof, Thomas G von Lueder, Hans Wedel, Giuseppe Rosano, Marcelo C Shibata, Alan Rigby, Marcus D Flather, Beta-Blockers in Heart Failure Collaborative Group

Research output: Contribution to journalArticlepeer-review

300 Citations (Scopus)
1516 Downloads (Pure)

Abstract

BACKGROUND: Atrial fibrillation and heart failure often coexist, causing substantial cardiovascular morbidity and mortality. β blockers are indicated in patients with symptomatic heart failure with reduced ejection fraction; however, the efficacy of these drugs in patients with concomitant atrial fibrillation is uncertain. We therefore meta-analysed individual-patient data to assess the efficacy of β blockers in patients with heart failure and sinus rhythm compared with atrial fibrillation.

METHODS: We extracted individual-patient data from ten randomised controlled trials of the comparison of β blockers versus placebo in heart failure. The presence of sinus rhythm or atrial fibrillation was ascertained from the baseline electrocardiograph. The primary outcome was all-cause mortality. Analysis was by intention to treat. Outcome data were meta-analysed with an adjusted Cox proportional hazards regression. The study is registered with Clinicaltrials.gov, number NCT0083244, and PROSPERO, number CRD42014010012.

FINDINGS: 18,254 patients were assessed, and of these 13,946 (76%) had sinus rhythm and 3066 (17%) had atrial fibrillation at baseline. Crude death rates over a mean follow-up of 1·5 years (SD 1·1) were 16% (2237 of 13,945) in patients with sinus rhythm and 21% (633 of 3064) in patients with atrial fibrillation. β-blocker therapy led to a significant reduction in all-cause mortality in patients with sinus rhythm (hazard ratio 0·73, 0·67-0·80; p<0·001), but not in patients with atrial fibrillation (0·97, 0·83-1·14; p=0·73), with a significant p value for interaction of baseline rhythm (p=0·002). The lack of efficacy for the primary outcome was noted in all subgroups of atrial fibrillation, including age, sex, left ventricular ejection fraction, New York Heart Association class, heart rate, and baseline medical therapy.

INTERPRETATION: Based on our findings, β blockers should not be used preferentially over other rate-control medications and not regarded as standard therapy to improve prognosis in patients with concomitant heart failure and atrial fibrillation.

FUNDING: Menarini Farmaceutica Internazionale (administrative support grant).

Original languageEnglish
Pages (from-to)2235-43
Number of pages9
JournalThe Lancet
Volume384
Issue number9961
Early online date2 Sept 2014
DOIs
Publication statusPublished - 20 Dec 2014

Bibliographical note

Copyright © 2014 Elsevier Ltd. All rights reserved.

Keywords

  • Adrenergic beta-Antagonists
  • Atrial Fibrillation
  • Electrocardiography
  • Heart Failure
  • Humans
  • Length of Stay
  • Patient Admission
  • Randomized Controlled Trials as Topic
  • Stroke

Fingerprint

Dive into the research topics of 'Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis'. Together they form a unique fingerprint.

Cite this